Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 10, Issue 10, Pages 1423-1432
Publisher
Informa Healthcare
Online
2014-09-06
DOI
10.1517/17425255.2014.943182
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Insomnia and Depression
- (2017) Daniel J. Taylor SLEEP
- Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
- (2014) Santiago Perez-Lloret et al. Expert Opinion On Drug Safety
- Novel levodopa formulations in the treatment of Parkinson's disease
- (2014) Manuela Pilleri et al. Expert Review of Neurotherapeutics
- Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms
- (2013) Makoto Naoi et al. Expert Review of Neurotherapeutics
- Current status of safinamide for the drug portfolio of Parkinson’s disease therapy
- (2013) Thomas Müller Expert Review of Neurotherapeutics
- Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease
- (2013) Thomas Müller Expert Review of Neurotherapeutics
- Rasagiline treatment effects on parkinsonian tremor
- (2013) Mark F. Lew INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria
- (2013) Makoto Naoi et al. JOURNAL OF NEURAL TRANSMISSION
- Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
- (2013) Jasmin Bartl et al. JOURNAL OF NEURAL TRANSMISSION
- Amantadine's role in the treatment of levodopa-induced dyskinesia
- (2013) R. L. Rodnitzky et al. NEUROLOGY
- Deep Brain Stimulation May Improve Quality of Life in People With Parkinson's Disease Without Affecting Caregiver Burden
- (2013) Genko Oyama et al. NEUROMODULATION
- Neurostimulation for Parkinson's Disease with Early Motor Complications
- (2013) W.M.M. Schuepbach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials
- (2013) Lawrence W. Elmer PARKINSONISM & RELATED DISORDERS
- Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial
- (2013) M. van Nimwegen et al. BMJ-British Medical Journal
- Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
- (2013) Kay Teo et al. Translational Neurodegeneration
- Community-Based Argentine Tango Dance Program Is Associated With Increased Activity Participation Among Individuals With Parkinson's Disease
- (2012) Erin R. Foster et al. ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
- Rasagiline
- (2012) Sheridan M. Hoy et al. DRUGS
- Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease
- (2012) Thomas Müller et al. JOURNAL OF NEURAL TRANSMISSION
- Amantadine: The journey from fighting flu to treating Parkinson disease
- (2012) G. Hubsher et al. NEUROLOGY
- What are the issues facing Parkinson's disease patients at ten years of disease and beyond?: Data from the NPF-QII study
- (2012) Anhar Hassan et al. PARKINSONISM & RELATED DISORDERS
- Drug therapy in patients with Parkinson’s disease
- (2012) Thomas Müller Translational Neurodegeneration
- Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinsonʼs Disease in the UK Setting:
- (2011) Norbert Kovacs et al. DRUGS & AGING
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
- (2011) Olivier Rascol et al. LANCET NEUROLOGY
- Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?
- (2011) Carl E. Clarke et al. MOVEMENT DISORDERS
- Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
- (2011) Peter Jenner et al. MOVEMENT DISORDERS
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
- (2011) Susan H. Fox et al. MOVEMENT DISORDERS
- Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro
- (2011) W Dimpfel et al. BMC Pharmacology & Toxicology
- MAO-inhibitors in Parkinson's Disease
- (2011) Peter Riederer et al. Experimental Neurobiology
- Levodopa delivery systems: advancements in delivery of the gold standard
- (2010) Ndidi Ngwuluka et al. Expert Opinion on Drug Delivery
- Dopaminergic therapy and subthalamic stimulation in Parkinson’s disease: a review of 5-year reports
- (2010) Luigi M. Romito et al. JOURNAL OF NEUROLOGY
- Does the clinical practice guideline on Parkinson’s disease change health outcomes? A cluster randomized controlled trial
- (2010) Astrid Larisch et al. JOURNAL OF NEUROLOGY
- Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease
- (2010) T. Muller et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- The Concept of Continuous Dopaminergic Stimulation: What We Should Consider when Starting Parkinson’s Disease Treatment
- (2010) Fabrizio Stocchi Neurodegenerative Diseases
- Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction?
- (2010) J. E. Ahlskog et al. NEUROLOGY
- Trials of neuroprotective therapies for Parkinson’s disease: Problems and limitations
- (2010) Raúl de la Fuente-Fernández et al. PARKINSONISM & RELATED DISORDERS
- Awareness and Knowledge of the Clinical Practice Guideline on Parkinson’s Disease among German Neurologists
- (2009) Karla Eggert et al. EUROPEAN NEUROLOGY
- The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
- (2009) Orit Bar-Am et al. JOURNAL OF NEUROCHEMISTRY
- Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease
- (2009) H. M. M. Smeding et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Direkte Kosten der Parkinson-Behandlung
- (2009) R. Ehret et al. NERVENARZT
- MAO-B INHIBITOR KNOW-HOW: BACK TO THE PHARM
- (2009) W. J. Burke et al. NEUROLOGY
- Mechanisms compensating for dopamine loss in early Parkinson disease
- (2009) J. Brotchie et al. NEUROLOGY
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of antiparkinsonian therapy during chronic subthalamic stimulation in Parkinson's disease
- (2009) M. Zibetti et al. PARKINSONISM & RELATED DISORDERS
- Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study
- (2008) Karsten Witt et al. LANCET NEUROLOGY
- Placebo influences on dyskinesia in Parkinson's disease
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now